Pemazyre (pemigatinib) is a targeted drug used for the treatment of specific types of cholangiocarcinoma. It exerts its therapeutic effect by inhibiting the abnormal activation of the FGFR2 gene. Despite its relatively good efficacy, patients need to understand its potential side effects to identify and manage them in a timely manner.

What Are the Side Effects of Pemazyre (Pemigatinib)?

Common Side Effects

(1) Skin and Hair Issues: Such as alopecia (hair loss), nail abnormalities (e.g., nail loss or deformation), and dry skin.

(2) Gastrointestinal Discomfort: Including diarrhea, nausea, vomiting, constipation, oral ulcers, and dry mouth.

(3) Systemic Symptoms: Fatigue, joint or back pain, taste changes, etc.

Severe Side Effects of Pemazyre (Pemigatinib) That Require Vigilance

Ocular Toxicity

(1) It may cause retinal pigment epithelial detachment (RPED), which manifests as blurred vision, floaters, or photopsia (sensation of flashing lights).

(2) Other ocular problems include dry eye syndrome and keratitis. It is recommended to conduct regular ophthalmic examinations before and during treatment; artificial tears may be used to relieve symptoms if necessary.

Hyperphosphatemia

(1) Elevated blood phosphorus levels are a pharmacodynamic effect of pemigatinib, but severe cases may lead to muscle spasms, perioral numbness, etc.

(2) It needs to be controlled through a low-phosphorus diet, drug intervention, or dosage adjustment, and blood phosphorus levels should be monitored regularly.

Embryo-Fetal Toxicity

(1) Pemigatinib may cause harm to the fetus and is contraindicated in pregnant women.

(2) Patients of childbearing age must use effective contraceptive measures during treatment and within 1 week after discontinuing the drug.

Precautions for Taking Pemazyre (Pemigatinib)

Dosage and Administration Method

(1) The drug must be taken strictly as prescribed by the doctor; swallow the tablet whole and do not crush or chew it.

(2) If a dose is missed for more than 4 hours or vomiting occurs after taking the drug, do not make up for the missed dose and take the next dose as originally scheduled.

Drug Interactions

(1) Avoid concurrent use with strong CYP3A inhibitors or inducers; if co-administration is unavoidable, dosage adjustment is required.

(2) Grapefruit-containing products may interfere with the drug's efficacy and should be avoided.

High-Risk Populations

(1) Lactating women need to suspend breastfeeding during treatment.

(2) Elderly patients or those with hepatic or renal impairment require individualized evaluation before using the drug.